Episode
VTE Risk Model in Children and a Novel Tri-specific T-cell-engager for MM
- Podcast
- Blood Podcast
- Published
- Feb 19, 2026
- Duration seconds
- 1021
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/97e8c581
Actions
POST https://stenobird.com/v1/public/podcasts/blood-podcast-664776/episodes/vte-risk-model-in-children-and-a-novel-tri-specific-t-cell-engager-for-mm/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-podcast-664776/vte-risk-model-in-children-and-a-novel-tri-specific-t-cell-engager-for-mm.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Julie Jaffray and Ulrike Philippar on their latest articles published in Blood . Dr. Jaffray discusses her CME article, " Multisite validation of a venous thrombosis risk model in critically ill children through the CHAT Consortium ", identifying patients with risks as high as 17% and taking research one step closer to the goal of personalized thromboprophylaxis for safe and effective care of high-risk children. Dr. Philippar discusses her article " Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models ", where the extensive in vitro and in vivo preclinical studies with cell lines and patient samples indicate strong potential for this agent to have efficacy against MM expressing either or both of these antigens.